So Yoon Sim is a technical officer in the Department of Immunization, Vaccines, and Biologicals at the World Health Organization, in Geneva, Switzerland. She was a health economist and research associate in the Department of International Health, Johns Hopkins Bloomberg School of Public Health, in Baltimore, Maryland, when this work was performed. Sim and Elizabeth Watts share credit as co-first authors.
Elizabeth Watts (
Health Aff (Millwood). 2020 Aug;39(8):1343-1353. doi: 10.1377/hlthaff.2020.00103.
Estimating the value of global investment in immunization programs is critical to helping decision makers plan and mobilize immunization programs and allocate resources required to realize their full benefits. We estimated economic benefits using cost-of-illness and value-of-a-statistical-life approaches and combined this estimation with immunization program costs to derive the return on investment from immunization programs against ten pathogens for ninety-four low- and middle-income countries for the period 2011-30. Using the cost-of-illness approach, return on investment for one dollar invested in immunization against our ten pathogens was 26.1 for the ninety-four countries from 2011 to 2020 and 19.8 from 2021 to 2030. Using the value-of-a-statistical-life approach, return on investment was 51.0 from 2011 to 2020 and 52.2 from 2021 to 2030. The results demonstrate continued high return on investment from immunization programs. The return-on-investment estimates from this study will inform country policy makers and decision makers in funding agencies and will contribute to efforts to mobilize resources for immunization. Realization of the full benefits of immunization will depend on sustained investment in and commitment to immunization programs.
估算全球免疫规划投资价值对于帮助决策者规划和调动免疫规划以及分配实现其全部效益所需的资源至关重要。我们使用疾病成本和生命统计价值方法来估计经济效益，并将这一估计与免疫规划成本相结合，得出 2011 年至 2030 年期间，94 个低收入和中等收入国家针对十种病原体的免疫规划投资回报率。使用疾病成本法，2011 年至 2020 年期间，94 个国家每投资 1 美元用于预防我们十种病原体的免疫接种，回报率为 26.1，2021 年至 2030 年期间为 19.8。使用生命统计价值法，2011 年至 2020 年的投资回报率为 51.0，2021 年至 2030 年的投资回报率为 52.2。研究结果表明，免疫规划继续具有很高的投资回报率。本研究的投资回报率估计将为国家决策者和供资机构的决策者提供信息，并有助于为免疫规划调动资源。实现免疫规划的全部效益将取决于对免疫规划的持续投资和承诺。
